AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2022
Feb 22, 2022
32418_dirs_2022-02-22_5f91b850-7fe9-401f-9f44-d7cab984c277.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2022-02-17
Reporting Person: FARR KEVIN M (CHIEF FINANCIAL OFFICER)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-17 | Employee Stock Options (right to buy) | $2.67 | A | 122374 | Acquired | 2032-02-16 | Common Stock (122374.0) | Direct |
Footnotes
F1: One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter.
More from Niagen Bioscience, Inc.
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2025
Dec 22
Director's Dealing
2025
Nov 17
Regulatory Filings
2025
Nov 6